Experimental CAR t therapy takes aim at stubborn AL amyloidosis
NCT ID NCT07250269
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment called GC012F for people with AL amyloidosis that has come back or not responded to other therapies. GC012F is a type of immunotherapy that uses a patient's own immune cells, modified to attack two specific targets on the abnormal cells causing the disease. The study will enroll 9 adults to check safety and see if the treatment can reduce signs of the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GC012F (a dual-target CAR T cell therapy that attacks two proteins on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat AL amyloidosis, potentially controlling the disease and improving organ function.
What could go wrong
This is a very early Phase 1 trial with only 9 participants, so it's too small to prove effectiveness. CAR T therapy can cause serious side effects like cytokine release syndrome, and the long-term benefits are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBeijing, 100034, China
-
Research Site
RECRUITINGBeijing, 100070, China
-
Research Site
RECRUITINGBeijing, CN-100730, China
-
Research Site
RECRUITINGChangchun, 130021, China
-
Research Site
RECRUITINGGuangzhou, 510100, China
-
Research Site
NOT_YET_RECRUITINGHangzhou, 310003, China
-
Research Site
RECRUITINGSuzhou, 215006, China
-
Research Site
RECRUITINGWenzhou, 325000, China
-
Research Site
NOT_YET_RECRUITINGWuhan, 430022, China